In:
Liver International, Wiley, Vol. 32, No. 9 ( 2012-10), p. 1434-1442
Abstract:
Ethanol injection is the best‐known image‐guided percutaneous ablation for hepatocellular carcinoma ( HCC ) and a well‐tolerated, inexpensive procedure with few adverse effects. However, there have been few reports on its long‐term results. Aims We report a 20‐year consecutive case series at a tertiary referral centre. Methods We performed 2147 ethanol injection treatments on 685 primary HCC patients and analysed a collected database. Results Final computed tomography demonstrated complete ablation of treated tumours in 2108 (98.2%) of the 2147 treatments. With a median follow‐up of 51.6 months, 5‐, 10‐ and 20‐year survival rates were 49.0% [95% confidence interval ( CI ) = 45.3–53.0%], 17.9% (95% CI = 15.0–21.2%) and 7.2% (95% CI = 4..5–11.5%) respectively. Multivariate analysis demonstrated that age, C hild– P ugh class, tumour size, tumour number and serum alpha‐fetoprotein level were significant prognostic factors for survival. Five‐, 10‐ and 20‐year local tumour progression rates were 18.2% (95% CI = 15.0–21.4%), 18.4% (95% CI = 15.2–21.6%) and 18.4% (95% CI = 15.2–21.6%) respectively. Five‐, 10‐ and 20‐year distant recurrence rates were 53.5% (95% CI = 49.4–57.7%), 60.4 (95% CI = 56.3–64.5%) and 60.8% (95% CI = 56.7–64.9%) respectively. There were 45 complications (2.1%) and two deaths (0.09%). Conclusions Ethanol injection was potentially curative for HCC , resulting in survival for more than 20 years. This study suggests that new ablation therapies will achieve similar or even better long‐term results in HCC .
Type of Medium:
Online Resource
ISSN:
1478-3223
,
1478-3231
DOI:
10.1111/liv.2012.32.issue-9
DOI:
10.1111/j.1478-3231.2012.02838.x
Language:
English
Publisher:
Wiley
Publication Date:
2012
detail.hit.zdb_id:
2102783-3
detail.hit.zdb_id:
2124684-1
Permalink